Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Asthma, Respiratory Disease, Fragility
Phase Not Applicable
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to determine the level of respiratory dysfunction, symptoms and frailty in patients with asthma according to different endophenotypes (allergic and eosonophilic asthma). In the light of the data obtained, it is thought that rehabilitation approaches that can be determined according to different endophenotypes in line with the evaluated parameters will guide health professionals working in this field. Hypotheses H0: There is no difference between allergic and eosonophilic asthmatics in terms of pulmonary function, respiratory dysfunction, symptoms, dyspnoea, fatigue, rhinitis, perception of breathlessness in activities of daily living, asthma control, level of frailty or quality of life. H1: There is a difference between individuals with allergic and eosonophilic asthma in terms of pulmonary function, respiratory dysfunction, symptoms, dyspnoea, fatigue, rhinitis, perception of breathlessness in activities of daily living, asthma control, level of frailty or quality of life.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Primary Outcomes

  • Respiratory Symptoms (One day)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-08-01
Completion: 2026-12-01
Eligibility
Age: 35 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hacettepe University
Principal Investigators:
  • Ebru Calik Kutukcu (PRINCIPAL_INVESTIGATOR) - Hacettepe University
  • Aynur Demirel, PhD (STUDY_DIRECTOR) - Hacettepe University
Contact Information
Study Contact:
Ebru Calik Kutukcu, PhD
3123051576
ebru.calik@hacettepe.edu.tr
Hacer Oncu, MsC
+905422305093
haceroncu1997@gmail.com
Ebru Calık Kutukcu, Phd
0903123051576
ebrucalk85@hotmail.com
Hacettepe University
Interventions
N/A
Study Locations (1 sites)
Hacettepe University, Ankara, State 06100 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Age between 35-75 years, * Diagnosed with allergic or eosonophilic asthma according to the Global Strategy for the Prevention and Treatment of Asthma (GINA). Exclusion Criteria: * Known cognitive impairment, * Having had an acute asthma attack in the last 6 weeks, * Having changed medication in the last 4 weeks.
Conditions Asthma, Severe Asthma, Uncontrolled Asth...
Phase Not Applicable
Enrollment 46
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

Asthma is a serious long-term lung condition caused by swollen airways that narrow. This causes wheezing, chest tightness, and breathlessness. Most asthma is well-controlled with medication. However, 5-10% of asthmatics have severe asthma where treatment does not control symptoms and up to 67% of asthmatics have uncontrolled asthma, caused by not always taking medication as recommended, lifestyle choices or other health problems worsening their asthma. In the UK, asthma affects around 800,000 young adults. This group is at high-risk of having poor asthma control, worse outcomes than other age-groups. This is because young adults need care that differs from other age-groups and current care is not meeting these needs. There is little information on the experiences and needs of this group and very few studies exist, exploring how to improve care. This study will explore the experiences and needs of young adults (age16-25) with severe and uncontrolled asthma. Methods. The investigators will perform two study-arms with young adults with severe/uncontrolled asthma in Manchester and Liverpool severe asthma centres: Study-arm 1: Interview participants using photographs chosen by them to help explain their experiences of living with asthma and support that they need. Study arm 2: Perform group interviews to understand participants' thoughts around the insights from study-arm 1 combined with their own experiences. To explore and develop ideas on how to improve future care. At the end of both study arms, a workshop involving patients and stakeholders involved in delivering care will take place, to identify a joint goal of how to improve care in this cohort and map ways in which to achieve this. Together, the study results and workshop will increase our understanding of the experiences and needs of young adults with asthma. Helping us to identify new ways to improve care which can be tested in future research.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Interventions / Regimen

  • Other: one to one interviews and or focus groups — one to one interviews and or focus groups

Primary Outcomes

  • Patient perceived experiences and challenges of living with severe and or uncontrolled asthma (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-11-25
Completion: 2025-10-31
Eligibility
Age: 16 Years – 25 Years
Sex: ALL
Volunteers: false
Enrollment: 46 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Manchester University NHS Foundation Trust
Collaborators: Burdett Trust for Nursing, Liverpool University Hospitals NHS Foundation Trust, University of Manchester
Contact Information
Study Contact:
Leanne - Jo Holmes, Mres
+44 01619987070
leannejo.holmes@mft.nhs.uk
Leanne J Holmes, Masters in reserach
4401619987070
leannejo.holmes@mft.nhs.uk
Severe asthma services based at both Manchester University Foundation NHS trust and Liverpool University Foundation NHS Trust
Leanne J Holmes, Masters in research
Severe asthma services based at both Manchester University Foundation NHS trust and Liverpool University Foundation NHS Trust
Interventions
  • Other: one to one interviews and or focus groups — one to one interviews and or focus groups
Study Locations (1 sites)
Severe asthma services based at both Manchester University Foundation NHS trust and Liverpool University Foundation NHS Trust, Manchester, Greater M239LT United Kingdom
Eligibility Criteria
Inclusion Criteria: * A confirmed diagnosis of severe or uncontrolled asthma under the care of the Manchester or Liverpool severe asthma services * Participants aged 16-25 years. * Informed consent provided. Exclusion Criteria: * Inability to provide informed consent. * Participants with additional long-term conditions who identify their dominant health concern to be non-asthma related. * Focus group only- inability to converse in English
Conditions Premature Birth, Asthma in Children, Sle...
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

Despite improved survival of extremely premature infants in recent decades, neonatal intensive care unit (NICU) graduates are diagnosed with asthma, sleep disordered breathing (SDB) in childhood, and neurodevelopmental impairments (NDI) at significant rates, disproportionate to their term peers. Early detection and intervention are critical to mitigate the impact of these impairments. Mechanisms leading from premature birth to these undesirable outcomes remain unclear, and accurate prognostic measures are lacking. This study wants to learn if these problems are related to certain patterns of breathing that babies had while they were in the NICU.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Asthma (5 years ± 6 months of age)
  • Sleep Disordered Breathing (SDB) (5 years ± 6 months of age)
  • Neurodevelopmental Impairment (NDI) (5 years ± 6 months of age)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-11-01
Completion: 2027-12-30
Eligibility
Age: 30 Weeks – 83 Months
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
Collaborators: University of Virginia, Case Western Reserve University, University of Miami, Northwestern University, National Heart, Lung, and Blood Institute (NHLBI), University of Alabama at Birmingham
Principal Investigators:
  • Debra Weese-Mayer, MD (PRINCIPAL_INVESTIGATOR) - Ann & Robert H Lurie Children's Hospital of Chicago
  • Anna Maria Hibbs, MD (PRINCIPAL_INVESTIGATOR) - Case Western Reserve University
  • Ambalavanan Namasivayam, MD (PRINCIPAL_INVESTIGATOR) - University of Alabama at Birmingham
Contact Information
Study Contact:
Erin Smith Lonergan
312-227-3300
ersmith@luriechildrens.org
Casey Rand
312-227-3300
crand@luriechildrens.org
Erin Lonergan, RRT, MS
Ann & Robert H. Lurie Children's Hospital of Chicago
Interventions
N/A
Study Locations (1 sites)
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois 60611 United States
Eligibility Criteria
Inclusion Criteria: * Enrolled in any Institutional Review Board (IRB) protocol of the Pre-Vent Study that had signed consent, or in any IRB protocol of the Pre-Vent Study that authorized re-contact for future research * Born \<29 weeks gestational age * Age at enrollment less than 7 years old Exclusion Criteria: * Subject was withdrawn from the Pre-Vent study after signing Pre-Vent consent form, for any reason * Subject had no physiological data recorded as part of Pre-Vent * Lack of regulatory approval from local IRB or Department of Children and Family Services (DCFS) to recontact subjects * Adopted by non-consenting family * Parent refused further contact, prior to approach for Post-Vent * Infant enrolled in Pre-Vent at Washington University St Louis, which is not a Post-Vent participating site.
Conditions Asthma
Phase PHASE2
Enrollment 780
Locations 167 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This study will compare an asthma inhaler that uses a new climate friendly alternative propellant to an asthma inhaler with an existing propellant. We want to make sure both versions of the inhaler work the same way for people with mild to moderate asthma.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: CHF5993 pMDI with HFA-152a — two puffs BID (twice daily)
  • Drug: CHF5993 pMDI with HFA-134a — two puffs BID
  • Drug: CHF718 pMDI with HFA-134a — two puffs BID

Primary Outcomes

  • Change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve from time zero to 4 hours (AUC0-4h) on Day 1 (Day 1)
  • Change from baseline in pre-dose FEV1 on Day 28 (Day 28)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-12-17
Completion: 2027-06-03
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 780 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chiesi Farmaceutici S.p.A.
Principal Investigators:
  • Piotr KUNA, MD (PRINCIPAL_INVESTIGATOR) - Barlicki University Hospital Medical University of Lodz, Poland
Contact Information
Study Contact:
Chiesi Clinical Trial Info Chiesi Clinical Trials
+39 0521 2791
clinicaltrials_info@chiesi.com
Alejandro Salvado
Hospital Británico de Buenos Aires_Site n. 032029
Miguel Angel Bergna
Centro Medico de Enfermedades Respiratorias_Site n. 032002
Interventions
  • Drug: CHF5993 pMDI with HFA-152a — two puffs BID (twice daily)
  • Drug: CHF5993 pMDI with HFA-134a — two puffs BID
  • Drug: CHF718 pMDI with HFA-134a — two puffs BID
Study Locations (167 sites)
Hospital Británico de Buenos Aires_Site n. 032029, Buenos Aires, 1275 Argentina
Centro Medico de Enfermedades Respiratorias_Site n. 032002, Buenos Aires, 1602 Argentina
Centro Medico Respire_Site n. 032014, Buenos Aires, 1646 Argentina
Asociación de Fomento y Sala de Primeros Auxilios "Alberto Mignaburu"_Site n. 032018, Buenos Aires, 1887 Argentina
Centro de Investigaciones Médicas Mar del Plata_Site n. 032019, Buenos Aires, 7600 Argentina
Fundacion CIDEA_Site n. 032009, Buenos Aires, C1121ABE Argentina
Centro Medico Arsema_Site n. 032003, Buenos Aires, C1427BCR Argentina
Centro de Investigaciones Metabólicas (CINME)_Site n. 032025, Ciudad Autonoma de Buenos Aire, 1056ABJ Argentina
Centro de Medicina Respiratoria - Concepcion del Uruguay_Site n. 032015, Ciudad Autonoma de Buenos Aire, 1056ABJ Argentina
CARE - Centro de Alergia y Enfermedades Respiratorias_Site n. 032028, Ciudad Autonoma de Buenos Aire, 1414 Argentina
Eligibility Criteria
Inclusion Criteria: * Male and female adults (18 ≤ age ≤ 75 years) with a diagnosis of Asthma for at least 6 months prior to screening and with diagnosis before the age of 50 years; * Non-smokers, ex-smokers; * Body mass index: within the range of 18.0 to 35.0 kg/m2 inclusive; * Stable asthma therapy: a stable maintenance treatment for at least 4 weeks prior to screening with: 1. low or medium doses of ICS (Inhaled Corticosteroids) alone; or 2. low or medium doses of ICS + LABA (Long-acting β2-agonist) (fixed or free combination). * Controlled or partly controlled based on an Asthma Control Questionnaire - 7 Items (ACQ-7) score \<1.5 at screening and at randomisation. * Pre-BD (Bronchodilator) FEV1 \>40% and \<90% of the predicted normal value, after appropriate wash out from BDs, at the Screening Visit (V1). * A demonstrated increase in either FEV1 or forced vital capacity of \>12% and \>200 mL from baseline within 30 minutes (min) after inhalation of 400 µg salbutamol (i.e. albuterol) pMDI at the Screening Visit (V1). Exclusion Criteria: * History of near fatal asthma or hospitalisation for asthma in intensive care unit, inpatient setting or emergency room access for asthma in the previous 6 months prior to screening, which in the judgement of the Investigator may place the subjects at undue risk; * Recent asthma exacerbation requiring systemic corticosteroids (SCSs), or emergency room admission or hospitalisation within 3 months prior to screening and/or during the run-in period ; * Non-persistent asthma: exercise-induced, seasonal asthma (as the only asthma-related diagnosis) not requiring daily asthma control medicine; * Asthma subjects currently treated with any of the following : 1. High dose ICS; 2. Long-acting muscarinic antagonist (LAMA); 3. Systemic, depot or slow-release corticosteroids within 12 weeks prior to screening; 4. Any other asthma treatments (e.g. cromolyn sodium, nedocromil sodium, leukotriene modifiers) within 4 weeks prior to screening; 5. Any biologic therapy (e.g. omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab) within 6 months prior to screening; * Respiratory disorders other than asthma * Lung resection; * Lower respiratory tract infection; * Lung cancer and history of lung cancer; * Subjects with active cancer or a history of cancer (other than lungs) ; * Patients who have clinically significant cardiovascular condition; * Run-in compliance: e-Diary completion \<75% and run-in treatment compliance \<75% at randomisation;
Conditions Asthma
Phase PHASE3
Enrollment 1038
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase 3 single-centre open label randomised controlled trial with two equal sized groups to assess the efficacy of budesonide/formoterol 80/4.5 (6-11 years) and 160/4.5 (12-18 years) compared to the standard of care in reducing asthma exacerbations over 52 weeks. Children and adolescents with a diagnosis of asthma or newly diagnosed with asthma will be screened for eligibility for enrolment. Those who had an asthma exacerbation in the previous year will be randomised 1:1, to either receive budesonide/formoterol inhaler for both symptom relief and for chronic anti- inflammatory maintenance therapy or the standard of care which is separate inhalers for symptom relief (short acting bronchodilator salbutamol) and chronic maintenance therapy with inhaled corticosteroids (beclomethasone or budesonide) and/or long-acting beta agonists or montelukast as determined by treating physicians. All asthma exacerbations and clinic/hospital admissions will be recorded for the duration of the 52-week follow-up. Participants will be followed up at 13, 26, 39 and 52 weeks. The 13- and 39-week visit will be telephonic visits to capture the primary end-point i.e. asthma exacerbations. Adverse events and medication changes data will also be collected. An independent Data and Safety Monitoring Board (DSMB) will be convened for this study with expertise in asthma and asthma clinical trials. The purpose of the DSMB will be to monitor the study for safety and operational futility with pre-defined stopping criteria. In addition, a Trial Steering Committee (TSC) will also provide overall supervision of the trial and ensure the trial is delivered in accordance with ICH-GCP. The TSC has been established with an independent Chair and include additional independent members including an observer early career researcher. Representatives of the Trial Funder (NIHR) and Sponsor (AHRI) will be invited to all TSC meetings.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Budesonide/formoterol — The Investigational Medicinal Product (IMP) consists of a combination of Budesonide (corticosteroid) and Formoterol Furamate (fast-acting β2 agonist) dihydrate. The IMP is currently available and registered in dry powder form turbuhaler (Symbicort) and a pressurised metered dose inhaler (Vannair). The recommended doses are pMDI/DPI 80/4.5 1-2 puffs twice daily OR 1 puff as needed (a maximum daily dose of 8 puffs) for children 6-11 years of age and 160/4.5 1-2 inhalations twice daily or 1 puff as needed (a maximum daily dose of 12 puffs) for adolescents 12-18 years.
  • Drug: standard of care — Any therapy that is prescribed as per asthma guidelines i.e. beclomethasone, budesonide and salbutamol, montelukast etc

Primary Outcomes

  • Number of exacerbations in 52 weeks ( End of study) (52 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-06-06
Completion: 2028-12-31
Eligibility
Age: 6 Years – 18 Years
Sex: ALL
Volunteers: false
Enrollment: 1038 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of KwaZulu
Principal Investigators:
  • Limakatso Lebina, PhD (STUDY_DIRECTOR) - Africa Health Research Institute
Contact Information
Study Contact:
Refiloe Masekela, PhD
800-555-5555
masekelar@ukzn.ac.za
Nompumelelo Ngobese
800-555-5555
nompumelelo.ngobese@ahri.org
Sbekezelo Hlophe
0720238851
sbehlophe@gmail.com
Africa Research Health Institute Clinical Trial Unit
Interventions
  • Drug: Budesonide/formoterol — The Investigational Medicinal Product (IMP) consists of a combination of Budesonide (corticosteroid) and Formoterol Furamate (fast-acting β2 agonist) dihydrate. The IMP is currently available and registered in dry powder form turbuhaler (Symbicort) and a pressurised metered dose inhaler (Vannair). The recommended doses are pMDI/DPI 80/4.5 1-2 puffs twice daily OR 1 puff as needed (a maximum daily dose of 8 puffs) for children 6-11 years of age and 160/4.5 1-2 inhalations twice daily or 1 puff as needed (a maximum daily dose of 12 puffs) for adolescents 12-18 years.
  • Drug: standard of care — Any therapy that is prescribed as per asthma guidelines i.e. beclomethasone, budesonide and salbutamol, montelukast etc
Study Locations (2 sites)
Africa Research Health Institute Clinical Trial Unit, Mtubatuba, KwaZulu-Natal 3935 South Africa
Africa Research Health Institute Clinical Trial Unit, Mtubatuba, KwaZulu-Natal 3965 South Africa
Eligibility Criteria
Inclusion Criteria: * Age for inclusion children and adolescents 6-18 years at the time of consent * Known asthmatic on treatment. * Newly diagnosed asthma based on investigator review and/or medical report. * All patients will have their asthma diagnosis confirmed (both new or known asthmatic patients) by either spirometry with reversibility or excessive diurnal variability by PEFR twice daily over 2 weeks. * Ability to perform Peak Expiratory Flow rate and/or bronchodilator reversibility testing. * Only participants with mild, or moderate asthma , based on medical history * At least one exacerbation of asthma in the past year as defined by an event requiring treatment with systemic corticosteroids for ≥3 days and/or a hospitalisation/emergency room visit for asthma requiring treatment with systemic corticosteroids. * Written consent from the participant or parent/guardian and assent from study participants where applicable. * Participant and/or parent/guardian agrees to comply with the study procedures, including the completion of the visits and be available for contact for telephonically for the non-contact visits Exclusion Criteria: * Tuberculosis (TB): active TB disease and contact with people with active TB disease in the last 6 months. * Chronic sputum expectoration, chest pain, shortness of breath, dizziness, or light-headedness in the last 2 months. * Cardiac arrythmia. * Chronic conditions: thyrotoxicosis, phaeochromocytoma, cardiovascular disease, severe hypertension. * Uncontrolled diabetes mellitus * Patients with Peak Expiratory Flow Rate \< 50% of predicted , as these would be classified as severe asthmatics. * Patients with any history of life-threatening asthma, defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma related syncopal episode(s). * Any use of biological therapy or immunomodulatory therapy such as methotrexate or regular oral prednisolone for the asthma management (STEP 5 GINA therapy). * Any surgical or medical condition that would significantly alter the absorption, distribution, metabolism or excretion of the IMP which may jeopardise the safety of the participants. The investigator should make this determination in consideration of the volunteer's medical history. * Any physical, mental or social condition, laboratory abnormality of history of illness that in the investigator's judgement might jeopardise the safety of the participant in the context of the study or might interfere with study procedures or the ability of the participant to adhere to and complete the study. The investigator should make this determination consideration of the volunteer's medical history. * Inability to present for follow-up or leaving the study area within 12 months of enrolment.
Conditions Asthma
Phase PHASE2
Enrollment 216
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

What is the goal of this study? The goal of this clinical trial is to find out whether the study drug LQ036 (a nebulized solution taken by inhaling through a nebulizer) works to improve lung function and asthma control in people whose asthma is not well controlled. The study will also learn about the safety of LQ036, how the body processes it, and whether the body develops an immune response to it. What are the main questions? The most important question is: • Does LQ036 improve lung function (measured by FEV₁ - the amount of air you can blow out in one second) more than a placebo at Week 12? Other important questions include: * Does LQ036 improve lung function at other time points (weeks 1, 2, 4, 8, 16, 20, 24)? * Does LQ036 reduce asthma attacks (sudden worsening of asthma that needs extra treatment)? * Does LQ036 help people use less rescue medication (inhaler for quick relief) and have more days without asthma symptoms? * Does LQ036 improve scores on asthma control and quality of life questionnaires? * What medical problems do participants have when taking LQ036?

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Biological: Placebo — Placebo is a look-alike solution for nebulization that contains no active drug. Participants will self-administer the placebo once daily by inhaling the nebulized solution.
  • Biological: LQ036 — LQ036 is a single-domain antibody formulated as a solution for nebulization. Participants will self-administer the assigned dose once daily by inhaling the nebulized solution.

Primary Outcomes

  • Absolute Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12 (Baseline, Week 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-09-30
Completion: 2027-12
Eligibility
Age: 12 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 216 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Novamab Biopharmaceuticals Co., Ltd.
Contact Information
Study Contact:
Meng Huang
86+02120985259
mhuang@novamab.com
Jieming Qu, Principal Investigator
+86-21-64370045
Jmqu0906@163.com
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Wei Tang, Principal Investigator
+86-21-64370045
Tw10986@rjh.com.cn
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Interventions
  • Biological: Placebo — Placebo is a look-alike solution for nebulization that contains no active drug. Participants will self-administer the placebo once daily by inhaling the nebulized solution.
  • Biological: LQ036 — LQ036 is a single-domain antibody formulated as a solution for nebulization. Participants will self-administer the assigned dose once daily by inhaling the nebulized solution.
Study Locations (1 sites)
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Eligibility Criteria
Inclusion Criteria: * Outpatients, aged 12 to 75 years inclusive, male or female, with body mass index (BMI) between 18 and 30 kg/m² inclusive. For participants aged 12 to 17 years, body weight must be ≥30 kg. * Diagnosed with bronchial asthma according to the 2025 Global Initiative for Asthma (GINA) guidelines prior to screening, with a documented history of asthma for ≥12 months. * For at least 3 months prior to screening, the participant has used inhaled corticosteroids (ICS) combined with at least one controller medication, and has maintained a stable treatment regimen and dosage for at least 1 month prior to screening. Low, medium, and high maintenance doses of ICS are defined according to the 2025 GINA guidelines (if multiple nebulized or combined administration methods are used, doses are to be combined). * At screening, pre-bronchodilator FEV₁ is ≥40% and \<80% of the predicted normal value. For participants on low-dose ICS, pre-bronchodilator FEV₁ is ≥40% and \<85% of the predicted normal value. * At screening, Asthma Control Questionnaire-5 (ACQ-5) score ≥1.5. * At screening, a positive bronchodilator reversibility test (increase in FEV₁ of ≥12% and an absolute increase of ≥200 mL, 15-30 minutes after inhalation of 400 μg salbutamol). If the reversibility test does not reach the positive threshold, one additional test is permitted within 7 days (excluding the day of the initial test). Alternatively, documented evidence of a positive bronchodilator reversibility test within 2 years prior to screening is acceptable. * At screening, blood eosinophil (EOS) count ≥150 cells/μL or fractional exhaled nitric oxide (FeNO) ≥25 ppb. * Experienced ≥1 severe exacerbation within the 12 months prior to screening (not required for participants on low-dose ICS). * Participants fully understand the purpose, nature, methods, and possible adverse reactions of the study, voluntarily agree to participate, and sign the informed consent form before any study procedures begin. * At randomization, pre-bronchodilator FEV₁ has increased by ≤20% from the screening value, and remains ≥40% and \<80% of the predicted normal value (for participants on low-dose ICS, pre-bronchodilator FEV₁ is ≥40% and \<85% of the predicted normal value). * At randomization, ACQ-5 score ≥1.5. * During the run-in period, participant compliance with run-in medication and background medication is ≥80% and ≤120%, compliance with daily diary completion is ≥80%, and there are complete data for at least 4 days within the 7 days prior to randomization. Exclusion Criteria: * Life-threatening asthma, defined as an asthma episode requiring intubation within 1 year prior to screening or during the run-in period, and/or a history of hypercapnia, respiratory arrest, hypoxic seizures, asthma-related syncopal episodes, etc. * Experienced a severe asthma exacerbation within 1 month prior to screening. * History of allergy to biologics, or known hypersensitivity to any component of the investigational product. * Use of biologics (including but not limited to anti-IgE, anti-IL-5, anti-IL-5 receptor, anti-IL-4/13 receptor, anti-TSLP monoclonal antibodies, etc.) and/or systemic immunosuppressants (including but not limited to methotrexate, cyclosporine, mycophenolate mofetil, tacrolimus, penicillamine, sulfasalazine, hydroxychloroquine, azathioprine, cyclophosphamide) for inflammatory diseases within 8 weeks or 5 half-lives (whichever is longer) prior to screening. * Received intravenous immunoglobulin (IVIG) or allergen-specific immunotherapy (SIT) within 3 months prior to screening. * Received systemic corticosteroids (excluding topical, ophthalmic, or intranasal corticosteroids), antibiotics, antifungals, antivirals, antiparasitic drugs, non-selective beta-blockers, or herbal medicines with anti-asthmatic effects within 1 month prior to screening or during the run-in period. * Received live or attenuated vaccine within 3 months prior to screening, or plan to receive live or attenuated vaccine during the study period. * Underwent bronchial thermoplasty within 12 months prior to screening. * Underwent major surgery within 8 weeks prior to screening, or plans to undergo surgery requiring general anesthesia or hospitalization for \>1 day during the study period. * In the investigator's judgment, presence of respiratory diseases other than asthma, including but not limited to chronic obstructive pulmonary disease (COPD), asthma-COPD overlap syndrome (ACOS), or any other significant lung disease (e.g., active pneumonia, idiopathic pulmonary fibrosis, pneumothorax, atelectasis, pulmonary fibrosis, bronchopulmonary dysplasia, bronchiectasis, etc.), that may place the participant at undue risk or affect the evaluation of study results. * Based on imaging and investigator judgment, presence of active tuberculosis or non-tuberculous mycobacterial infection, untreated latent tuberculosis, or history of incompletely treated tuberculosis. * Active autoimmune disease or autoimmune disease requiring immunosuppressive therapy, such as rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc. * Blood EOS \>1500 cells/μL at screening, or other systemic diseases that may cause elevated peripheral blood EOS count (e.g., hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis, eosinophilic esophagitis, etc.), which in the investigator's judgment may affect the evaluation of the drug. * Known or suspected immunodeficiency, including history of invasive opportunistic infection (e.g., histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) even if resolved; or presence of unusually frequent, recurrent, or prolonged infections suggestive of an immunocompromised state. * Known parasitic infection, or suspected or high-risk parasitic infection in the investigator's judgment. * Active infection (e.g., upper respiratory tract infection) within 1 month prior to screening or during the run-in period, or acute infection requiring systemic anti-infective therapy. * History of lymphoproliferative disease or malignancy (participants with basal cell carcinoma, localized squamous cell carcinoma of the skin, or cervical carcinoma in situ are eligible if they have completed curative treatment and have had no evidence of recurrence for at least 12 months prior to signing informed consent), or other medical history that in the investigator's judgment may affect the evaluation of the drug. * Presence of any other severe and/or uncontrolled disease or treatment that, in the investigator's judgment, may affect the evaluation of the drug, including but not limited to: severe neurological disease, severe mental disorder, uncontrolled diabetes mellitus, uncontrolled hypertension, major cardiovascular disease, corrected QT interval prolongation (male \>450 ms, female \>470 ms, Fridericia's formula), or persistent arrhythmia. * Current smoker or cessation of smoking for \<6 months; or former smoker with a smoking history of ≥10 pack-years (pack-years = \[cigarettes per day / 20\] × years of smoking). * Positive serology for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus antibody, or Treponema pallidum antibody at screening (participants with positive HBsAg but HBV-DNA below the lower limit of detection, or positive HCV antibody but HCV-RNA below the lower limit of detection, are eligible). * Participants with severe liver or kidney dysfunction, such as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>3 × upper limit of normal (ULN), or serum creatinine \>1.5 × ULN. * Pregnant or breastfeeding women; women planning to become pregnant during the study or within 3 months after the end of the study; fertile women or men who, in the investigator's judgment, cannot use medically accepted reliable contraception from signing informed consent until 3 months after the last dos
Conditions Asthma
Phase PHASE3
Enrollment 1000
Locations 102 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

An event-driven, Phase III study to evaluate the efficacy and safety of BDA MDI compared with AS MDI in reducing the risk of a severe asthma exacerbation in symptomatic Chinese adults with asthma.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Combination Product: Budesonide/Albuterol metered dose inhaler, MDI — Combination Product (Drug + Device)
  • Combination Product: Albuterol sulfate metered dose inhaler, MDI — Combination Product (Drug + Device)

Primary Outcomes

  • Time to first severe asthma exacerbation (24 to 52 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-06-17
Completion: 2027-10-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
  • Combination Product: Budesonide/Albuterol metered dose inhaler, MDI — Combination Product (Drug + Device)
  • Combination Product: Albuterol sulfate metered dose inhaler, MDI — Combination Product (Drug + Device)
Study Locations (102 sites)
Research Site, Baotou, 014010 China
Research Site, Baotou, 14010 China
Research Site, Beijing, 100020 China
Research Site, Beijing, 100029 China
Research Site, Beijing, 100039 China
Research Site, Beijing, 100191 China
Research Site, Changchun, 130021 China
Research Site, Changchun, 130041 China
Research Site, Changsha, 410005 China
Research Site, Changsha, 410015 China
Eligibility Criteria
Inclusion Criteria: 1. Documented physician-diagnosed asthma for at least 12 months prior to Visit 1 2. Receiving 1 of the scheduled asthma maintenance therapies for 3 months with stable dosing for at least the last 4 weeks before Visit 1 3. Pre-bronchodilator FEV1 of ≥ 40% to \< 90% predicted normal value for adults. 4. Documented reversibility to albuterol 5. A documented history of at least one severe asthma exacerbation within 12 months before Visit 1 6. ACQ-7 score ≥ 1.5 assessed at Visit 1 7. ACQ-5 score ≥ 1.5 assessed at Visit 2 8. Receiving inhaled SABA as needed prior to Visit 1 for at least 3 months 9. Use of Sponsor-provided salbutamol sulfate inhalation aerosol as needed medication due to asthma symptoms on at least 3 days during the last week of the run-in period before Visit 2 10. Demonstrate acceptable MDI administration technique as assessed by the investigator; use of spacers is prohibited 11. Able to perform acceptable and reproducible PEF measurements as assessed by the investigator 12. BMI \< 40 kg/m2 13. Negative pregnancy test (urine at Visit 1) for female participants of childbearing potential 14. Women of childbearing potential must agree to prevent pregnancy 15. Compliance: must be willing to remain at the study site as required per protocol and complete all visit assessments Exclusion Criteria: 1. Chronic obstructive pulmonary disease or other significant lung disease 2. Oral/SCS use (any dose) within 6 weeks before Visit 1 3. Chronic use of OCS ≥ 3 weeks use in 3 months prior to Visit 1 4. Having received any marketed or investigational biologic within 3 months or 5 half-lives before Visit 1, whichever is longer, or any other prohibited medication 5. Current smokers, former smokers with \> 10 pack-years history, or former smokers who stopped smoking \< 6 months before Visit 1 6. Life-threatening asthma as defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma related syncopal episode(s) within last 5 years of Visit 1 7. Completed treatment for lower respiratory infection or asthma exacerbation within 6 weeks of Visit 1 8. Upper respiratory infection involving antibiotic treatment not resolved within 7 days before Visit 1 9. Clinically significant laboratory abnormalities 10. Historical or current evidence of a clinically significant disease 11. Cancer not in complete remission for at least 5 years before Visit 1 12. History of psychiatric disease, intellectual deficiency, poor motivation, or other conditions if their magnitude is limiting informed consent validity 13. Have a known or suspected hypersensitivity to albuterol/salbutamol, or budesonide and/or their excipients 14. Inability to abstain from protocol-defined prohibited medications during the study 15. Having received a live attenuated vaccination within 7 days of Visit 1 16. Currently pregnant or breastfeeding 17. Participants who experience \> 1 asthma exacerbation during the screening period
Conditions Allergic Asthma
Phase PHASE2
Enrollment 100
Locations 13 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy and safety of FB825 in adult patients with moderate-to-severe allergic asthma.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: FB825 — FB825 will be administered at 8 mg/kg for the first dose and 4 mg/kg for the other five doses.
  • Drug: Placebo — Placebo will be administered at 8 mg/kg for the first dose and 4 mg/kg for the other five doses.

Primary Outcomes

  • Occurrence of an exacerbation of asthma at week 24 after first dosing. (week 24)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-07-27
Completion: 2027-12
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Oneness Biotech Co., Ltd.
Collaborators: Microbio Shanghai Co., Ltd.
Principal Investigators:
  • Sam Kuo (PRINCIPAL_INVESTIGATOR) - Oneness Biotech Co., Ltd.
Contact Information
Study Contact:
June Kuo
+886 2 2703 1098
June.Kuo@onenessbio.com.tw
Pei-Jin Ho
+886 2 2703 1098
Peijin.Ho@onenessbio.com.tw
Chien-Hao Lai
Kaohsiung Chang Gung Medical Foundation
Interventions
  • Drug: FB825 — FB825 will be administered at 8 mg/kg for the first dose and 4 mg/kg for the other five doses.
  • Drug: Placebo — Placebo will be administered at 8 mg/kg for the first dose and 4 mg/kg for the other five doses.
Study Locations (13 sites)
Kaohsiung Chang Gung Medical Foundation, Kaohsiung City, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan
Far Eastern Memorial Hospital, New Taipei City, Taiwan
China Medical University Hospital, Taichung, Taiwan
Taichung Venterans General Hospital, Taichung, Taiwan
National Cheng Kung University Hospital, Tainan, Taiwan
Linkou Chang Gung Memorial Hospital, Taipei, Taiwan
MacKay Memorial Hospital, Taipei, Taiwan
Ministry of Health and Welfare Shuang-Ho Hospital, Taipei, Taiwan
National Taiwan University Hospital, Taipei, Taiwan
Eligibility Criteria
Inclusion Criteria: 1. Male or females 18-75 years old. 2. Subjects diagnosed with moderate-to-severe allergic asthma \[Global Initiative for Asthma \[GINA\]; GINA, 2021) at least 12 months prior to Visit 1. 3. Documented reversibility from historical data of at least 12% and 200 mL in FEV1 after the administration of 200 to 400 mcg albuterol/salbutamol (or other standard office practice) OR documented airway hyperresponsiveness (methacholine PC20 \< 8 mg/mL \[or PC20 \< 16 mg/mL on ICS\]) OR airflow variability in clinic FEV1 \>12% and 200 mL between visits outside of respiratory infections, documented in the past 24 months prior to Visit 1 if documented reversibility and airway hyperresponsiveness data are not available. 4. Subjects must have a pre-bronchodilator FEV1 value of ≥ 40% and ≤ 80% predicted within 2 months from randomization. 5. Subjects must have received a physician-prescribed asthma regimen with medium- or high-dose ICS plus LABA for at least 3 month prior to Visit 1 and the dose of ICS must be stable for at least 30 days prior to Visit 1 and throughout the screening period. 1. High-dose ICS is defined as total daily dose of \>500 mcg fluticasone propionate or equivalent 2. Medium-dose ICS is defined as a total daily dose of 250 to 500 mcg fluticasone propionate or equivalent. 3. Equivalence ICS doses will be based upon the GINA guidelines (GINA, 2021) 4. According to the medical history, subject have no more than a maximum of 2000 mcg/day equipotent ICS daily dosage of fluticasone propionate or equivalent in 3 months before visit 1. 6. Prior to screening, subjects must be on a stable dose of any of the following doses and formulations of ICS/LABA combination therapy for at least 1 month: 1. Fluticasone/salmeterol combination therapy * Advair® Diskus - dry powder inhaler (DPI): 250/50 μg BID or 500/50 μg BID, or * Advair® HFA - metered dose inhaler (MDI): 230/42 μg BID or 460/42 μg BID, or 2. Budesonide/formoterol combination therapy (Symbicort® -160/4.5 μg BID or 320/9 μg BID), or 3. Mometasone/formoterol combination therapy (Dulera® -200/10 μg BID or 400/10 μg BID). 4. Other equivalents medium to-high dose medication following the GINA guidelines (GINA, 2021) 7. Subjects must have a documented history of protocol-defined asthma exacerbation at least 1 or more times within the 12 months. 8. A total serum IgE ≥ 125 IU/mL during screening prior to randomization. 9. Subjects must have at least one positive in skin prick test or at least one environmental allergen-specific IgE greater than normal range. 10. Uncontrolled asthma demonstrated both during the screening period and at the time of randomization defined as ACQ-5 (5-item Asthma Control Questionnaire) ≥ 1.5 11. If recently treated for respiratory tract infection, the treatment must have been completed at least 4 weeks prior to screening. Subjects who have an upper respiratory tract infection during screening are allowed to be rescreened 4 weeks after resolution. 12. Female subjects of childbearing potential must use at least two forms of birth control. One must be barrier protection (i.e., condom or female condom) and the other is one of acceptable method of birth control (ie, diaphragm, intrauterine device, hormonal contraceptives, or abstinence) throughout the study. Subjects who are surgically sterile (ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), or postmenopausal (defined as amenorrhea for 12 consecutive months and documented serum follicle stimulating hormone level \>40 mU/mL) will be considered as no childbearing potential. All female subjects of child-bearing potential must have a negative serum pregnancy test at screening. Note: The subject must use the methods of contraception mentioned above during study period and at least 120 days after the last dosing of FB825. 13. The subject has a body weight ≥ 40 kg at screening. 14. The subject has a normal or non clinically significant abnormal, as determined by the investigator, 12-lead electrocardiogram (ECG). 15. The subject is able to provide written informed consent. 16. The subject agrees to comply with all protocol requirements. Exclusion Criteria: 1. Asthma exacerbation or any other reason requiring systemic steroids in the 30 days prior to randomization. Subjects are allowed to be rescreened 30 days after completion of treatment. 2. \>20% relative change in post-bronchodilator FEV1 between screening and randomization. 3. Female subjects who are pregnant or lactating. 4. A positive human immunodeficiency virus (HIV) test (e.g., HIV Ag/Ab combo test) at screening or subject taking antiretroviral medications, as determined by medical history. 5. Patients with positive HBeAg or HCV RNA results should be excluded as they are indications of active Hepatitis B virus and Hepatitis C virus replication. 6. Active lung diseases (e.g., bronchitis, chronic obstructive pulmonary disease) other than allergic asthma. 7. Use of any experimental drug within 30 days or 5 half-lives, whichever is longer, prior to or during the screening period. 8. Current or history of treatment with a monoclonal antibody, for example, IL-4, IL-5, IL-13 or IL-15 antibody treatment within 6 months prior to the screening. 9. Current or history of treatment with anti-IgE antibody treatment within 6 months or 5 half-lives, whichever is longer. 10. The subject has a history of alcohol or drug abuse that would impair or risk the patients' full participation in the study, in the opinion of the investigator. 11. The subject has any condition that, in the opinion of the investigator, would compromise the study or the well-being of the subject or prevent the subject from meeting or performing study requirements. 12. The subject has indication of severe liver disease, defined by serum levels of either alanine aminotransferase (ALT), aspartate transaminase (AST) above 3x upper limits of normal (ULN) or elevated total bilirubin \>2x ULN as determined at screening. 13. The subject has severe kidney disease, defined as estimated GFR \<30ml/min/1.73m2 or creatinine \> 3x ULN. 14. The subject has known or suspected history of immunosuppression or immunodeficiency. 15. Known history of active tuberculosis (TB) or evidence of tuberculosis infection as defined by a positive purified protein derivative (PPD) skin test and/or interferon-gamma release assay. The interferon-gamma release assay should be repeated in case of an indeterminate result. 16. The subject has history of malignancy within 5 years before the screening period. Patients with non-invasive carcinoma in-situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin may be eligible if they have undergone curative resection at least 12 months prior to screening. 17. Current smoker with \> 10 packs year prior to screening. A smoker is defined as a subject who has taken inhaled nicotine containing products (e.g. cigarette, cigar, pipe), including e-cigarettes prior to screening. 18. High risk of parasite infection • Risk factors for parasitic disease (living in an endemic area, travel within the last 6 months to regions where geohelminthic infections are endemic, and/or chronic immunosuppression). AND • Evidence of parasitic colonization or infection on stool evaluation for ova and parasites. Note: stool ova and parasite evaluation will only be conducted in patients with risk factors and an eosinophil count more than twice the upper limit of normal. 19. The subject has received live vaccine within 12 weeks or COVID-19 vaccination within 2 weeks prior to dosing or planned live attenuated vaccinations during the study. 20. The subject has a history of any clinically relevant arrhythmias as determined by the investigator. 21. The subject has a history of respiratory failure or near fatal asthma events which resulted in intensive care unit admission or intubation within five years before the screening period.
Conditions Asthma Acute, Asthma Exacerbation, Asthm...
Phase PHASE4
Enrollment 1860
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The study is a randomized controlled trial on the effect of emergency department initiation of Airsupra on acute asthma "recurrence" at 3 months and other related outcomes (acute asthma relapse, asthma control).

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Airsupra — 1 dose (2 inhalations) PRN, with maximum of 6 doses (12 inhalations) in a 24-hour period

Primary Outcomes

  • acute asthma recurrence (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-11-07
Completion: 2027-06
Eligibility
Age: 18 Years – 54 Years
Sex: ALL
Volunteers: false
Enrollment: 1860 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Contact Information
Study Contact:
Carlos A Camargo, MD, DrPH
617-726-5276
ccamargo@mgb.org
Charles L Emerman, MD
617-726-5276
cemerman@metrohealth.org
MetroHealth
Interventions
  • Drug: Airsupra — 1 dose (2 inhalations) PRN, with maximum of 6 doses (12 inhalations) in a 24-hour period
Study Locations (1 sites)
MetroHealth, Cleveland, Ohio 44109 United States
Eligibility Criteria
INCLUSION CRITERIA: * acute asthma * age 18.0 to 54.9 years * English and/or Spanish speaking * decision by ED attending to discharge patient to home on short course of systemic corticosteroids * (intervention group only) Willingness to use Airsupra as their rescue inhaler for next 3 months * demonstration of acceptable MDI administration technique * provision of informed consent prior to any study-specific procedures EXCLUSION CRITERIA: * involvement in the planning and/or conduct of the study * previous enrolment in the present study * prior diagnosis of COPD, chronic bronchitis, or emphysema * use of systemic corticosteroids in the past 2 weeks * participation in another clinical study with an investigational product during the past 4 weeks or the 3 months after enrollment in the current study * concurrent pneumonia * clinically significant cardiovascular disease or clinically significant cancer * patients with known hypersensitivity to Airsupra, albuterol sulfate, budesonide, or any of the excipients of the product * (for women only, by self-report): * currently pregnant * currently breastfeeding, * (among sexually active women of child-bearing age only) not using adequate contraception over the last 3 months, or no plan to use adequate contraception over the next 3 months * lack of a working cell phone and working email address * expected lack of availability for text and/or telephone follow-up at approximately 3, 6, and 12 weeks after the ED visit * inability to provide an alternate contact with a working cell phone and working email address.
Conditions Fibromyalgia, Depression - Major Depress...
Phase NA
Enrollment 36
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

Repetitive Transcranial Magnetic Stimulation (rTMS) of the motor cortex is a recognized analgesic technique for the treatment of fibromyalgia pain, which represents a largely unmet medical need. However, the effectiveness of motor cortex rTMS is inconsistent, being observed in only about 40% of patients and not always long-lasting. It has been previously shown that predictive factors for a lack of response to motor cortex rTMS include the presence of depressive symptoms, and that prefrontal cortex rTMS is not effective for pain, even though this treatment has proven efficacy in major depressive disorder. The hypothesis is that targeting both the motor and prefrontal cortices with rTMS will yield a particularly beneficial effect in fibromyalgia patients presenting with comorbid depressive symptoms. Given the absence of established biomarkers for predicting rTMS response, an additional aim will be to develop reliable indicators of rTMS efficacy, based on clinical phenotype and measurements of oscillatory patterns assessed by electroencephalogram (EEG) recordings.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: rTMS — The active protocol will include 5 daily stimulation sessions during the first week (D1-D5), followed by one session per week for 3 weeks (W2, W3, W4), then 2 sessions spaced 2 weeks apart (W6, W8), for a total of 10 stimulation sessions. Evaluation will continue until 2 weeks after the final stimulation, that is, at week 10 after the start of treatment.
  • Device: Sham — The sham protocol will follow an identical session schedule. Participants will be randomized to either the active or sham group in a parallel-group design, meaning each participant will receive only one of the two treatments throughout the entire duration of the study.

Primary Outcomes

  • Change in average pain intensity over 10 weeks (Brief Pain Inventory) (From enrollment to Week 10.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-09
Completion: 2028-11
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospital Ambroise Paré Paris
Contact Information
Study Contact:
Nadine ATTAL
+33 1 49 09 59 31
nadine.attal@aphp.fr
Elisa UMMARINO
+33 1 49 09 45 56
elisa.ummarino@inserm.fr
Nadine ATTAL
+33 1 49 09 59 31
nadine.attal@aphp.fr
Hopital Ambroise-Paré INSERM U987, 9 Av. Charles de Gaulle
Interventions
  • Device: rTMS — The active protocol will include 5 daily stimulation sessions during the first week (D1-D5), followed by one session per week for 3 weeks (W2, W3, W4), then 2 sessions spaced 2 weeks apart (W6, W8), for a total of 10 stimulation sessions. Evaluation will continue until 2 weeks after the final stimulation, that is, at week 10 after the start of treatment.
  • Device: Sham — The sham protocol will follow an identical session schedule. Participants will be randomized to either the active or sham group in a parallel-group design, meaning each participant will receive only one of the two treatments throughout the entire duration of the study.
Study Locations (1 sites)
Hopital Ambroise-Paré INSERM U987, 9 Av. Charles de Gaulle, Boulogne-Billancourt, Île-de-France Region 92100 France
Eligibility Criteria
Inclusion Criteria: * Chronic pain lasting at least 6 months, with or without associated depressive symptoms; * Fibromyalgia (2016 revised ACR criteria and a FIRST questionnaire score of at least 5 out of 6); * Average pain intensity ≥ 4/10 on a 0-10 numeric rating scale; * Pain present daily or almost daily (≥ 4 days per week); * Patients aged over 18 and under 80 years; * Patients who have provided written informed consent; * Patients whose analgesic treatment has been stable for at least 1 month prior to inclusion and will not need to be modified during the study; * Patients who can be followed for the duration of the study (10 weeks); * Patients covered by a health insurance plan or otherwise eligible. Exclusion Criteria: * Ongoing litigation; * Contraindication to rTMS: * Implanted electronic devices and/or conductive objects near the coil: Patients with an active implanted device that is activated or controlled by physiological signals (e.g., pacemakers, implantable cardiac defibrillators \[ICD\], vagus nerve stimulators \[VNS\], wearable cardioverter defibrillators \[WCD\], ocular implants, deep brain stimulation systems, drug infusion pumps or ports, intracardiac leads), even if the device has been removed. * Non-removable metallic objects near the coil:\*\* Patients with a conductive, ferromagnetic, or magnetically sensitive metal implant in the head or within 30 cm of the coil (e.g., cochlear implants, implanted electrodes/stimulators, aneurysm clips or coils, stents, or bullet fragments); * Current abuse of drugs or psychoactive substances, including alcohol (according to DSM-5 criteria); * Pregnancy or breastfeeding; * Epilepsy or a history of epilepsy; * Unstable or progressive medical conditions (e.g., cancer); * Psychosis according to DSM-5 criteria; * Presence of another pain condition more severe than the one qualifying for inclusion; * Failure to correctly complete pain self-assessment diaries between inclusion and randomization (fewer than 4 pain scores recorded over 7 days); * Inability to understand the informed consent form, or subjects under legal guardianship or curatorship; * Participation in another research protocol within 30 days prior to inclusion.

ETASCAN Project: ETAS Project 2

NCT07550140
Recruiting
Conditions Cognition, Affect (Mental Function), Sle...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to investigate the chronic effects of ETAS® on cognitive, affective and neural outcomes in healthy adults aged 60-80 years with mild to moderate subjective cognitive complaints.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: ETAS® — 1500mg ETAS®
  • Dietary Supplement: Placebo — Matched placebo capsule

Primary Outcomes

  • Montreal Cognitive Assessment (MoCA) score (From baseline (pre intervention) to week 12 (post intervention))
  • fMRI (From baseline (pre intervention) to week 12 (post intervention))
  • MRS (From baseline (pre intervention) to week 12 (post intervention))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-05
Completion: 2027-12-31
Eligibility
Age: 60 Years – 80 Years
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Reading
Collaborators: Amino Up Chemicals Co., Ltd.
Contact Information
Study Contact:
Piril Hepsomali, PhD
+44 118 378 5818
p.hepsomali@reading.ac.uk
Piril Hepsomali, PhD
+44 118 378 5818
p.hepsomali@reading.ac.uk
University of Reading, School of Psychology and Clinical Languages
Interventions
  • Dietary Supplement: ETAS® — 1500mg ETAS®
  • Dietary Supplement: Placebo — Matched placebo capsule
Study Locations (1 sites)
University of Reading, School of Psychology and Clinical Languages, Reading, Berkshire RG6 6ES United Kingdom
Eligibility Criteria
Inclusion Criteria: * Aging between 60-80 years old * Having normal vision and hearing * Having a body mass index between 18.5 and 30 * Having mild to moderate subjective cognitive complaints Exclusion Criteria: * Smoking * Having food allergies * Following restrictive and/or unbalanced diets (Appendix 6: Are you vegetarian or vegan? Yes / No; Are you currently on a weight-reducing or other special diet? Yes/No If 'Yes', please give details.) * Being diagnosed with any psychiatric or neurologic conditions (e.g. schizophrenia, depression, dementia) including eating disorders * Being diagnosed with any cardiometabolic diseases (including type II diabetes and cardiovascular disease), or hypertension or thrombosis related disorders or suffer from thyroid disease * Currently taking anticoagulants, antiplatelet medication, antidepressants, proton-pump inhibitors * Currently consuming prebiotic or probiotic supplements * Continuous antibiotic use for \> 3 days within 1 month prior to enrolment * Continuous use of weight-loss drug for \> 1 month before screening * Having a significant gastrointestinal (GI) condition affecting absorption including (but not limited to) inflammatory bowel disease; total colectomy or bariatric surgery; irritable bowel disease; end stage renal disease; active cancer, or treatment for any cancer, in last 3 years * History of claustrophobia * Fitted with a pacemaker or artificial heart valve * Have active implants, such as cochlear, ocular, or penile implant * Experience of metal fragments e.g. shrapnel in your eyes or any other part of your body * Drug infusion pump installed * Have any surgically implanted metal in any part of your body, other than dental fillings and crowns (e.g. joint replacement or bone re-construction) * Have had any surgery that might have involved metal implants * Current or historical experience of epilepsy * Have stimulators for nerves, brain or bone installed * Have an intrauterine contraceptive device installed (IUD) * Wear transdermal patches containing metal * Wear a filling, crown, dental post (entirely within the tooth) associated with root canal treatment, retainer, bridge or braces * For scanning, would need to remove coloured contact lenses, nail polish and makeup. * Hearing aid wearer * Body piercings that you cannot or will not remove for the scanning session * Have tattoos or permanent makeup
Conditions Depressive Disorder, Major
Phase NA
Enrollment 170
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research is to learn more about a new treatment for individuals with Major Depressive Disorder (MDD) with heightened symptoms of anhedonia (i.e. loss of pleasure or interest in activities). The treatment is called Prism, and it is a software device intended for a novel form of neurofeedback training to be used in a clinic setting. During this study, the subject will use different techniques to measure brain activities, including magnetic resonance imaging (MRI) and electroencephalography (EEG).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Prism Training — Participants will complete 20 Prism training sessions. The Prism training sessions take place twice a week over a 10-week period, with a minimum of one night of sleep between sessions. Participants will also receive two single booster sessions, 4 weeks and 8 weeks after their last NF session completed.

Primary Outcomes

  • HDRS-21 (Change from baseline to week 12 (post training visit))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-25
Completion: 2027-08-30
Eligibility
Age: 22 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 170 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: GrayMatters Health Ltd.
Principal Investigators:
  • Aron Tendler, MD (STUDY_DIRECTOR) - GrayMatters Health
Contact Information
Study Contact:
Adar Shani, MSc
+972-54-2347770
adar@graymatters-health.com
Jennifer Yarden, PhD
+972-52-4897823
jennifer@graymatters-health.com
Eric Tirrell
401-455-6633
ETirrell@Butler.org
Butler Hospital
Interventions
  • Device: Prism Training — Participants will complete 20 Prism training sessions. The Prism training sessions take place twice a week over a 10-week period, with a minimum of one night of sleep between sessions. Participants will also receive two single booster sessions, 4 weeks and 8 weeks after their last NF session completed.
Study Locations (3 sites)
Butler Hospital, Providence, Rhode Island 02906 United States
Houston Center For Advanced Psychiatric Treatment, Houston, Texas 77401 United States
Sheba Medical Center, Ramat Gan, Israel
Eligibility Criteria
Inclusion Criteria: 1. Primary Diagnosis of MDD with Anhedonia, established according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM5TR) - HDRS-17 score of ≥20, SHAPS-C score of ≥25. 2. Fluency in written and spoken English. 3. Able intellectually to understand the instructions 4. Ability to give signed, informed consent either written or electronic (via REDCap eConsent). 5. Normal or corrected-to-normal vision and hearing. 6. Ability to adhere to the study schedule. 7. Completed at least one antidepressant treatment course at an adequate dose and duration in the current episode per the ATRQ. Exclusion Criteria: 1. Contraindications to MRI (e.g., metal in the body, claustrophobia). 2. Any suicidal behavior in the past 1 year (i.e., actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior) assessed using Columbia -Suicide Severity Rating Scale (C-SSRS) prior to screening and during the screening period. 3. Diagnosis for current moderate or severe substance or alcohol use disorder (SUD/AUD) within the past month (as defined in DSM-5-substance use disorder). 4. Any unstable medical condition, as per the clinical judgement of the investigator. 5. Any change in, or initiation of, fluoxetine within the past 8 weeks or of other SSRIs/SNRIs antidepressants, bupropion, stimulants, or other psychiatric medications within the past 4 weeks. 6. Recent initiation (within the past 2 months) of psychotherapy; continuation of established maintenance supportive therapy will be permitted. 7. Enrollment in another therapeutic clinical study at screening or within 2 months prior to screening or intended enrollment within the duration of this study.